The uncovered molecular signatures offered mechanistic clues linking EMT, hormone resistance, and local immune status during lesion evolution and preliminary molecular evidence to support pathological stratification and targeted precision therapeutic strategies for PCa was provided.
Abstract
Background: Prostate cancer (PCa) exhibits strong multidimensional heterogeneity. The dynamic evolution of Luminal subsets and their crosstalk with the tumor microenvironment (TME) during malignant progression remain poorly understood. Conventional single-cell transcriptomics lacks spatial context, while low-resolution spatial technologies cannot resolve single-cell and subcellular interactions. This study aimed to map a high-resolution spatial transcriptomic atlas to characterize Luminal subset heterogeneity and stromal crosstalk across progressive PCa lesions. Methods: We used high-resolution CosMx spatial molecular imaging (SMI) to profile 6 treatment-naive PCa patients and constructed a single-cell spatial transcriptomic atlas covering 385 fields of view and 154,168 high-quality cells. Unsupervised clustering, functional enrichment, cell–cell communication analysis, and flow cytometry were performed. Results: We identified 28 cell clusters, including 8 Luminal subsets (0–7) and 9 Fibroblast subsets (0–8). Pathological microregion-specific spatial distribution was observed: Luminal 0–2 dominated in BPH/PIN, while Luminal 3–7 were enriched in poorly differentiated PCa and vacuolated adenocarcinoma. These subsets were functionally linked to androgen resistance, EMT, and immune regulation. COLLAGEN, FN1, and LAMININ were identified as key pathways mediating pathological-specific tumor–stromal crosstalk. Flow cytometry verified T-cell exhaustion and immunosuppression in the TME. Conclusions: This study delineated pathological microregion-specific Luminal subset plasticity and dynamic epithelial–stromal communication across the full spectrum of PCa lesions. The uncovered molecular signatures offered mechanistic clues linking EMT, hormone resistance, and local immune status during lesion evolution. Our spatial atlas provided preliminary molecular evidence to support pathological stratification and targeted precision therapeutic strategies for PCa.
Distinguishing indolent from aggressive tumors remains a key challenge in the clinical management of prostate cancer (PC), highlighting the need for better tools for accurate risk stratification. A defining feature of aggressive PC is its propensity for perineural invasion (PNI), a pathological finding that is associat...
P. V. Salachan, L. Raaby, Jacob Fredsøe et al.· Journal of Hematology & Onco...· 0 citations
Lung cancer remains one of the leading causes of cancer-related mortality worldwide; beyond its rising incidence, its marked molecular heterogeneity and complex tumor microenvironment (TME) hinder treatment response and drive resistance, contributing directly to its high mortality rate. Single-cell RNA sequencing (scRN...
C. Braicu, R. Pîrlog, A. Nutu et al.· Biochimica et biophysica act...· 0 citations
Bladder carcinoma in situ (CIS) is a multifocal, non–muscle-invasive disease with a high risk of progression to muscle-invasive cancer. Current management strategies are often guided by genomic profiling of single tumor samples, which incompletely capture tumor heterogeneity and may contribute to treatment failure. In...
Tyler D. Myers, A. Salmasi, M. Meagher et al.· bioRxiv· 0 citations
BACKGROUND
Liver cancer exhibits profound spatial and cellular heterogeneity, contributing to tumour progression, invasion and therapeutic resistance. Emerging evidence suggests that rare low-abundance malignant cell populations residing within discrete tissue niches influence these processes. However, their reliable d...
Hai Cheng, Yi-Bo Hou, Si-Yang Yu et al.· Gut· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.